HIGHLIGHTS
- who: Sara H. Keshavjee et al. from the Division of Surgical Oncology, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA have published the research: Gastric Cancer and the Immune System: The Key to Improving Outcomes?, in the Journal: Cancers 2022, 14, 5940. of /2022/
- what: This study showed increased overall survival of 13.8 months vs. 11.1 months (p=0.0046) in those with HER2+ GC treated with trastuzumab in combination with chemotherapy vs. chemotherapy alone, leading trastuzumab to become standard-of-care for advanced HER2+ GC patients. The addition . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.